September 2026 FDA Recall Buprenorphine Hydrochloride by Par Health Usa, Llc
D-0876-2026 - Crystallization

This Class II drug recall was voluntarily initiated by Par Health Usa, Llc on September 8, 2026 for the product Buprenorphine Hydrochloride. The FDA reported the reason for recall as crystallization. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0876-2026

Reason for Recall
Crystallization
Initiated
09-08-2026
Reported
10-07-2026
Quantity
154210 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05

Batch or Lot Expiration Information

Lot# :83912, Exp Date 10/2026
Lot# :84234, Exp Date 11/2026
Lot# :84990, Exp Date 11/2026
Lot# :85003, Exp Date 12/2026
Lot# :86443, Exp Date 01/2027
Lot# :89909, Exp Date 05/2027

Affected Packages Involved in this Recall